The first Phase III trials of an inactivated vaccine for COVID-19 in the United Arab Emirates has reached 31,000 vaccinated volunteers from more than 120 nationalities in only six weeks, making it the largest trial of the vaccine in the world.
The speed and efficiency of the operation is setting new global benchmarks for the trials of the vaccine developed by Sinopharm CNBG. The trials are being managed by G42 Healthcare in partnership with the Department of Health - Abu Dhabi, the UAE Ministry of Health and Prevention (MoHaP) and Abu Dhabi Health Services Company.
Thousands of volunteers have already received their second shot of the vaccine. They continue to undergo regular monitoring and health checks.
Due to the high number of participants, the vaccine centres at ADNEC and Al Qarain Center in Sharjah are now closed to new volunteers.
DoH has confirmed that there are now enough numbers of volunteers to complete the clinical trial.
The globally acknowledged trial numbers for programmes of this kind are typically around 45,000 or above. The trials are expected to reach that number soon.